Intelligence Briefing · ~5 min read
Crescent Pharma Faces Significant Risks from Ramipril Recall in Competitive Landscape
Cardiovascular · ACE Inhibitor
Type
Regulatory Context BriefingGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
6 items
Sources
6
Key Takeaways
Leadership-ready summary — read in 5 minutes.
- Regulatory risk is concentrated around Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28 (MHRA). Entity match (crescent pharma limited). Relevant agencies in corpus: MHRA, FDA. The recall may prompt scrutiny from health authorities, potentially leading to further regulatory actions that could impact compliance and future approvals.
- Elevated medium regulatory exposure for Crescent Pharma Limited could delay market entry or constrain labeling if agency review intensifies.
- Increased scrutiny from health authorities may result in additional regulatory actions affecting compliance.
Why It Matters
Strategic context for leadership and portfolio decision-making.
Regulatory risk is concentrated around Class 4 Medicines Defect Notification: Cadila Pharmaceuticals Limited, Mirtazapine 30mg Tablets, EL(26)A/28 (MHRA). Entity match (crescent pharma limited). Relevant agencies in corpus: MHRA, FDA. The recall may prompt scrutiny from health authorities, potentially leading to further regulatory actions that could impact compliance and future approvals.
Supporting Evidence
Evidence-backed items from the Humanexa intelligence graph.
Crescent Pharma recalls Ramipril 10mg capsules due to manufacturing error
Cardiovascular · ACE Inhibitor
Source: Safety Signal
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Crescent Pharma recalls Ramipril 10mg capsules due to manufacturing error
Cardiovascular · ACE Inhibitor
Insights
- Crescent Pharma Faces Significant Risks from Ramipril Recall in Competitive Landscape
Cardiovascular · ACE Inhibitor